Loading...
XSHE
300519
Market cap340mUSD
Jul 10, Last price  
15.35CNY
1D
-0.13%
1Q
19.41%
Jan 2017
-62.32%
IPO
57.89%
Name

Zhejiang Xinguang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
38.16
P/S
9.08
EPS
0.40
Div Yield, %
2.62%
Shrs. gr., 5y
0.11%
Rev. gr., 5y
-0.43%
Revenues
270m
-23.07%
229,617,378249,854,530267,937,988292,109,437311,478,232315,313,658310,865,113276,257,365291,262,099283,080,271320,876,074351,488,810270,399,837
Net income
64m
-40.86%
46,854,08956,837,67372,468,952105,651,545118,784,212118,958,793106,159,24687,995,76893,900,70698,976,352114,280,359108,821,01064,356,480
CFO
53m
-57.85%
0057,511,46699,820,100124,840,438121,184,880124,232,04992,772,34798,266,202112,611,669142,355,309126,429,39753,290,425
Dividend
May 29, 20240.4 CNY/sh

Profile

Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health foods. The company offers pharmaceutical products in the areas of cardiovascular and cerebrovascular diseases, and traumatic diseases, covering the aspects of respiratory system, digestive system, urinary system, pediatric diseases, and improving immunity. It also can produce 6 dosage forms with 49 approval numbers for drug production and 2 approval numbers for health food. It offers its products in the form of tablets, granules, syrups, powders, hard capsules, and oral solutions, as well as mixtures, including oral liquids. Zhejiang Xinguang Pharmaceutical Co., Ltd. was founded in 1970 and is headquartered in Shengzhou, China.
URL
IPO date
Jun 24, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
270,400
-23.07%
351,489
9.54%
Cost of revenue
196,248
221,237
Unusual Expense (Income)
NOPBT
74,152
130,251
NOPBT Margin
27.42%
37.06%
Operating Taxes
8,804
16,783
Tax Rate
11.87%
12.88%
NOPAT
65,348
113,469
Net income
64,356
-40.86%
108,821
-4.78%
Dividends
(80,000)
(96,000)
Dividend yield
3.00%
3.83%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
(145)
Long-term debt
1
Deferred revenue
6,842
7,708
Other long-term liabilities
2,362
2,362
Net debt
(720,341)
(737,174)
Cash flow
Cash from operating activities
53,290
126,429
CAPEX
(15,987)
Cash from investing activities
(51,374)
Cash from financing activities
(80,000)
(96,000)
FCF
50,851
113,262
Balance
Cash
698,946
737,030
Long term investments
21,396
Excess cash
706,821
719,455
Stockholders' equity
570,908
697,606
Invested Capital
282,417
148,185
ROIC
30.35%
73.54%
ROCE
8.69%
15.39%
EV
Common stock shares outstanding
160,891
160,000
Price
16.57
5.81%
15.66
-22.44%
Market cap
2,665,967
6.40%
2,505,600
-22.44%
EV
1,945,626
1,768,426
EBITDA
88,926
144,306
EV/EBITDA
21.88
12.25
Interest
16
14
Interest/NOPBT
0.02%
0.01%